Biospecimen sourcing looks like procurement and behaves like experimental design. The material you buy carries a donor, a collection history and a set of decisions that were made before you were involved, and all three arrive whether or not they appear on the invoice. Treating the purchase as a line item is how programmes end up with variance nobody can account for.
Know which kind of supplier you are talking to
| Type | Strength | Limit |
|---|---|---|
| Owns collection | Can schedule to your criteria and return to donors | Inventory breadth may be narrower than a marketplace |
| Biobank or repository | Large archived collections, sometimes with clinical annotation | What exists is what exists; nothing new can be collected |
| Marketplace or broker | Wide catalogue across many sources | Provenance is relayed rather than held; donor recall not possible |
| Clinical site network | Access to patient populations and clinical context | Processing and timing vary between sites |
None of these is better in the abstract. They are better for different questions, and the common error is assuming a marketplace can do what an owned collection does because both produce a certificate.
Fresh, frozen and fixed are different products
The format determines which questions the material can answer, and the decision is frequently made on convenience. Fresh material preserves cell state and constrains scheduling. Cryopreserved material decouples the experiment from the collection and introduces freeze-thaw effects that vary by cell type. Fixed or embedded material supports morphology and some molecular work and forecloses anything functional.
Choosing a format because it is available rather than because it suits the endpoint is one of the more expensive habits in this category.
What annotation is worth paying for
Demographics are usually included and rarely sufficient. What separates useful material is the annotation that predicts behaviour: HLA genotype, KIR genotype, prior viral exposure such as cytomegalovirus status, and for disease-state material, a confirmed diagnosis with enough clinical context to be interpretable.
Ask whether annotation was generated at programme level or on the lot you bought. Programme-level annotation is available as a selection criterion. Lot-level annotation is documentation, and by the time you have it, selection is over.
Consent and provenance cannot be retrofitted
Documented informed consent covering research use, obtained under an approved protocol, either exists in the record from the point of collection or it does not exist at all. This is the one attribute that cannot be added later, which makes it the one worth verifying first rather than last.
Ask who obtained consent. A supplier who collected the material answers directly. A supplier who acquired it relays an answer, which is a materially weaker position on exactly the attribute that has no remedy.
Disease-state material has its own rules
Patient-derived material is where sourcing gets genuinely difficult. Diagnosis has to be confirmed rather than self-reported, disease activity and treatment status shape the cells profoundly, and matched material from the same donor, such as serum or plasma alongside cells, is often what makes an experiment interpretable.
OrganaBio documents disease-state material across 24 autoimmune indications for research use, covering discovery, drug screening and biomarker work, with a viability specification of greater than 80% post-thaw. That specification is deliberately distinct from the healthy-donor material, and treating the two as interchangeable is a common error.
Specifying a request that gets a useful answer
State the cell type and format, the quantity and whether it is one lot or a series, the donor criteria that are genuine constraints as distinct from inherited preferences, the annotation you need attached rather than available on request, whether you will need the same donors again, and the grade. A request scoped that way can be answered accurately. A request for a cell type and a number will be answered with whatever is in stock.
OrganaBio’s catalogue spans leukopaks, cryopreserved PBMCs, isolated T and NK populations, and cord blood CD34+ HSCs, with donor characterisation applied at programme level. Supplier diligence more broadly is covered in how to evaluate a PBMC supplier.
Frequently asked questions
What types of biospecimen supplier are there?
Suppliers that own collection and can schedule to your criteria, biobanks holding archived collections, marketplaces and brokers offering breadth across many sources, and clinical site networks with access to patient populations. Each suits different questions, and a marketplace cannot do what an owned collection does even though both produce certificates.
How do I choose between fresh, cryopreserved and fixed material?
By the endpoint rather than by availability. Fresh preserves cell state and constrains scheduling, cryopreserved decouples the experiment from collection but introduces freeze-thaw effects, and fixed or embedded material supports morphology and some molecular work while foreclosing functional assays.
What donor annotation is worth paying for?
Annotation that predicts behaviour rather than describing demographics: HLA genotype, KIR genotype, prior viral exposure such as cytomegalovirus status, and for disease-state material a confirmed diagnosis with enough clinical context to interpret.
Why does it matter whether annotation is programme-level or lot-level?
Programme-level annotation exists before you order and can be used as a selection criterion. Lot-level annotation is generated on material you already bought, so by the time it exists the selection has already happened.
Can consent and provenance be established after collection?
No. Documented informed consent obtained under an approved protocol either exists in the record from the point of collection or it does not. It is the one attribute with no remedy, which makes it worth verifying first.
What is different about sourcing disease-state material?
Diagnosis must be confirmed rather than self-reported, disease activity and treatment status shape the cells substantially, and matched components from the same donor are often what make an experiment interpretable. Specifications also differ from healthy-donor material and should not be treated as interchangeable.
How should I write a biospecimen request?
State cell type and format, quantity and whether one lot or a series, genuine donor constraints as distinct from inherited preferences, the annotation you need attached rather than available on request, whether you will need the same donors again, and the grade.
Working through this on a live programme?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterisation, format selection and documentation scope.
